X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1301) 1301
Publication (83) 83
Book Review (18) 18
Magazine Article (15) 15
Book / eBook (4) 4
Book Chapter (4) 4
Conference Proceeding (2) 2
Web Resource (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (956) 956
male (820) 820
carbolines - therapeutic use (808) 808
tadalafil (616) 616
index medicus (495) 495
animals (409) 409
erectile dysfunction - drug therapy (369) 369
middle aged (343) 343
phosphodiesterase inhibitors - therapeutic use (294) 294
pharmacology & pharmacy (293) 293
adult (278) 278
carbolines - pharmacology (268) 268
female (261) 261
sildenafil citrate (257) 257
erectile dysfunction (247) 247
treatment outcome (239) 239
carbolines - adverse effects (212) 212
urology & nephrology (209) 209
aged (203) 203
piperazines - therapeutic use (201) 201
sildenafil (175) 175
phosphodiesterase 5 inhibitors - therapeutic use (172) 172
rats (165) 165
vardenafil dihydrochloride (154) 154
carbolines - administration & dosage (151) 151
impotence (147) 147
sulfones - therapeutic use (145) 145
imidazoles - therapeutic use (138) 138
mice (132) 132
double-blind method (126) 126
dose-response relationship, drug (119) 119
efficacy (118) 118
double-blind (115) 115
men (115) 115
purines - therapeutic use (114) 114
triazines - therapeutic use (100) 100
drug therapy (93) 93
purines (92) 92
time factors (91) 91
neurosciences (90) 90
vasodilator agents - therapeutic use (89) 89
phosphodiesterase inhibitors - adverse effects (86) 86
safety (86) 86
chemistry, medicinal (82) 82
care and treatment (73) 73
vardenafil (72) 72
hypertension, pulmonary - drug therapy (71) 71
carbolines (68) 68
analysis (67) 67
carbolines - chemistry (67) 67
gastrointestinal agents - therapeutic use (65) 65
beta-carboline alkaloids (64) 64
serotonin antagonists - therapeutic use (64) 64
cyclic nucleotide phosphodiesterases, type 5 (63) 63
psychiatry (63) 63
colonic diseases, functional - drug therapy (62) 62
rats, wistar (60) 60
research (60) 60
sulfones (60) 60
beta-carbolines (59) 59
erectile dysfunction - etiology (59) 59
patient satisfaction (59) 59
phosphodiesterase inhibitors - administration & dosage (58) 58
randomized controlled trials as topic (58) 58
alkaloids (57) 57
disease models, animal (57) 57
pharmacology (56) 56
surveys and questionnaires (56) 56
carbolines - pharmacokinetics (55) 55
adolescent (54) 54
medicine, general & internal (52) 52
drug administration schedule (51) 51
nitric-oxide (50) 50
phosphodiesterase inhibitors - pharmacology (49) 49
piperazines - adverse effects (49) 49
sexual disorders (49) 49
article (48) 48
clinical neurology (48) 48
indoles - therapeutic use (48) 48
penile erection - drug effects (48) 48
prostatic hyperplasia - drug therapy (48) 48
therapy (48) 48
drug interactions (47) 47
drug therapy, combination (47) 47
health aspects (47) 47
dosage and administration (46) 46
gastroenterology & hepatology (46) 46
quality-of-life (45) 45
aged, 80 and over (44) 44
anxiety (44) 44
drugs (43) 43
irritable bowel syndrome - drug therapy (43) 43
administration, oral (42) 42
cancer (42) 42
hypertension (42) 42
inhibitors (42) 42
international index (42) 42
placebo-controlled trial (42) 42
risk factors (42) 42
severity of illness index (42) 42
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1198) 1198
Chinese (44) 44
German (22) 22
Russian (19) 19
French (11) 11
Japanese (7) 7
Italian (4) 4
Polish (4) 4
Slovak (4) 4
Spanish (4) 4
Hungarian (3) 3
Czech (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lung Cancer, ISSN 0169-5002, 12/2017, Volume 114, pp. 12 - 22
SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development of chemo-resistant disease, less than 5% of patients... 
DNA Repair Pathways | Lung Cancer | Checkpoint Inhibitors | Small Cell Lung Cancer | PARP Inhibitors | TOPOISOMERASE-II-ALPHA | TUMOR-CELLS | AURORA KINASE | CELL LUNG-CANCER | WEE1 KINASE | ONCOLOGY | RESPIRATORY SYSTEM | HUMAN RAD51 PROTEIN | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | HOMOLOGOUS RECOMBINATION | PHASE-I | Lung Neoplasms - drug therapy | Humans | Rad51 Recombinase - antagonists & inhibitors | Aurora Kinases - therapeutic use | Small Cell Lung Carcinoma - drug therapy | Heterocyclic Compounds, 4 or More Rings - therapeutic use | DNA Damage - genetics | Genomic Instability - drug effects | Cell Cycle Checkpoints - genetics | Rad51 Recombinase - therapeutic use | Carbolines - therapeutic use | Genomic Instability - genetics | Molecular Targeted Therapy - methods | Benzimidazoles - therapeutic use | Cytotoxins - therapeutic use | DNA Damage - drug effects | Lung Neoplasms - genetics | Cell Proliferation - genetics | Etoposide - therapeutic use | Piperazines - therapeutic use | Small Cell Lung Carcinoma - genetics | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Azepines - therapeutic use | Phthalazines - therapeutic use | Cell Cycle Checkpoints - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | DNA Repair | Cell Proliferation - drug effects | Chemotherapy | DNA repair | Lung cancer | DNA damage | DNA | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article
Journal Article
Journal Article
Journal Article